Understanding cardiac safety early is critical in drug development. In their latest poster, Jazz Pharmaceuticals, explain how they utilised Metrion’s clinically translatable cardiotoxicity assay to do exactly that. The poster describes data from Metrion’s high-throughput VOLTA assay with human iPSC-derived cardiomyocytes, combined with patch-clamp IC50 data from cells expressing hERG, NaV1.5 and CaV1.2. Once again, Metrion’s specialist cardiotox scientists improved the ability to predict QTc and QRS changes and identify cardiovascular liabilities much earlier in the discovery process.
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.
Optical voltage imaging of human iPSC-derived cardiomyocytes was used to assess electrophysiological effects of compounds beyond hERG inhibition. Action potential waveform analysis revealed compound-specific and concentration-dependent changes, enabling mechanistic differentiation of multichannel activity and demonstrating a human-relevant approach for translational cardiac safety assessment.